Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.
暂无分享,去创建一个
D. Illingworth | E. Stein | R. Zupkis | R. Knopp | C. Dujovne | P. Frost | Y. Mitchel | P. Tun | P. Frost | R. Greguski
[1] Stanley Azen,et al. Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS) , 1993, Annals of Internal Medicine.
[2] P. Ridker,et al. A prospective study of lipoprotein(a) and the risk of myocardial infarction. , 1993, JAMA.
[3] F. Song,et al. Cholesterol lowering and mortality: the importance of considering initial level of risk. , 1993, BMJ.
[4] T. Miller,et al. Low-dose, time-release nicotinic acid: effects in selected patients with low concentrations of high-density lipoprotein cholesterol. , 1992, Mayo Clinic proceedings.
[5] P. Hickman,et al. Low-dose sustained release nicotinic acid (Tri-B3) and lipoprotein (a) , 1992, The American journal of cardiology.
[6] Angelo M. Scanu. Lipoprotein(a). A genetic risk factor for premature coronary heart disease. , 1992, JAMA.
[7] N. Nakaya,et al. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[8] J J Albers,et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.
[9] G. Walldius,et al. Effects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2, and HDL3, in hyperlipoproteinaemia , 1990, Journal of internal medicine.
[10] J. Johansson,et al. The effects of nicotinic acid treatment on high density lipoprotein particle size subclass levels in hyperlipidaemic subjects. , 1990, Atherosclerosis.
[11] A. Scanu,et al. Lipoprotein (a). Heterogeneity and biological relevance. , 1990, The Journal of clinical investigation.
[12] E. Boerwinkle,et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. , 1990, The New England journal of medicine.
[13] R. Kreisberg,et al. Effects of Simvastatin and Cholestyramine in Familial and Nonfamilial Hypercholesterolemia , 1990 .
[14] A. Hamsten,et al. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid , 1989, Journal of internal medicine.
[15] F. Sacks,et al. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. , 1989, The American journal of cardiology.
[16] G. Mullin,et al. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. , 1989, Annals of internal medicine.
[17] M. H. Luria,et al. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. , 1988, Archives of internal medicine.
[18] M. Tikkanen,et al. Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. , 1988, Atherosclerosis.
[19] S. Grundy. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. , 1988, The New England journal of medicine.
[20] D H Blankenhorn,et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.
[21] J. Stamler,et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.
[22] A. Pesce,et al. Enzyme-linked immunoabsorbant assay of apolipoprotein AII in plasma, with use of a monoclonal antibody. , 1986, Clinical chemistry.
[23] H. Brewer,et al. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. , 1985, Atherosclerosis.
[24] J. Albers,et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. , 1985, Metabolism: clinical and experimental.
[25] A. Gotto,et al. Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis. , 1984, Circulation.
[26] C. Packard,et al. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. , 1979, The Journal of clinical investigation.
[27] J. Stamler. Clofibrate and niacin in coronary heart disease. , 1975, JAMA.
[28] M. Puri. Combining independent one-sample tests of significance , 1967 .
[29] J. Klotz. The Wilcoxon, Ties, and the Computer , 1966 .
[30] H. L. Mason,et al. Nicotinic acid treatment of hypercholesteremia. Comparison of plain and sustained-action preparations and report of two cases of jaundice. , 1961, JAMA.
[31] W. Parsons. Studies of nicotinic acid use in hypercholesteremia. Changes in hepatic function, carbohydrate tolerance, and uric acid metabolism. , 1961, Archives of internal medicine.
[32] P. Toutouzas,et al. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group. , 1993, The American journal of cardiology.
[33] C. Shear,et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. , 1991, Archives of internal medicine.
[34] Daniel Steinberg,et al. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. , 1988, Archives of internal medicine.
[35] J. Albers,et al. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. , 1978, Journal of lipid research.